Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q4 2020 · 10-K
Revenue$238.49M$238.49M−4.3% vs Q4 2019 Net Income$17.62M$17.62M−15.4% vs Q4 2019 EPS Diluted$0.34$0.34−15.0% vs Q4 2019 Gross Profit$113,557,000+2.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$46,406,000+124.9% Free Cash Flowderived$35,760,000+416.6% Margins · derivedGross margin47.6%+3.0 pt vs Q4 2019
Operating margin10.9%+1.3 pt vs Q4 2019
Net margin7.4%−1.0 pt vs Q4 2019
ended Mar 28, 2020 · filed May 20, 2020 · 53 d after period end